VERTEX PHARMACEUTICALS INC / MA VRTX Income Statement

Vertex pharmaceuticals inc / ma (VRTX)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09
Revenues:
Revenues:
Revenues
4,819	4,162	3,619	3,454	3,265	3,047	2,829	2,622	2,414	2,488	2,295	2,131	2,018	1,702	1,661	1,557	1,291	1,032	758	628	600	580	787	829	1,002	1,211	1,194	1,309	1,416	1,527	1,756	2,079	1,775	1,410	912	277	194	143	111	112	100	101	0	0	0
Costs and expenses:
Cost of sales
615	547	485	464	433	409	371	332	299	275	250	231	204	206	209	186	157	117	66	46	40	39	41	51	66	88	151	161	241	236	184	188	89	63	0	0	0	-	-	0	-	-	-	-	-
Royalty expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	3	4	4	5	7	8	11	17	21	27	30	36	41	44	45	41	43	38	33	27	16	12	12	12	12	13	13	13	14	0	0	0
Research and development expenses
1,863	1,754	1,712	1,486	1,445	1,416	1,285	1,409	1,361	1,324	1,266	1,083	1,065	1,047	1,109	1,083	1,036	995	887	831	832	855	903	932	930	909	873	853	827	806	779	768	745	707	690	671	653	637	603	565	549	550	0	0	0
Sales, general and administrative expenses
693	658	616	594	574	557	539	522	512	496	471	456	440	432	419	413	395	376	358	334	317	305	302	313	342	361	396	407	418	436	448	461	440	400	341	279	223	187	157	145	137	130	0	0	0
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
6	4	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restructuring (income) expenses
-	-	-	-	-	0	0	0	4	14	14	13	10	1	2	4	6	2	4	43	41	50	74	45	46	40	13	1	1	1	2	1	1	2	-1	0	1	1	5	5	4	6	0	0	0
Intangible asset impairment charges
-	-	-	-	-	29	0	255	255	255	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	663	412	412	412	0	0	105	105	105	0	0	0	-	-	-	-	0	-	-	-
Acquisition-related expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	0	0	0
Total costs and expenses
3,178	2,965	2,845	2,574	2,482	2,412	2,195	2,521	2,433	2,365	2,258	1,786	1,723	1,692	1,744	1,692	1,601	1,499	1,325	1,267	1,248	1,272	1,599	1,624	1,672	2,104	1,891	1,882	1,944	1,524	1,452	1,559	1,410	1,296	1,189	969	890	839	787	737	712	715	0	0	0
Income from operations
1,640	1,197	773	880	783	635	633	101	-18	123	37	344	295	9	-83	-134	-309	-466	-566	-638	-648	-692	-812	-794	-670	-892	-696	-573	-527	2	303	520	365	113	-276	-692	-695	-696	-676	-624	-612	-614	0	0	0
Interest income
60	63	65	58	48	38	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2	2	2	1	1	1	2	5	0	0	0
Interest expense
29	28	33	37	40	72	41	8	-23	-57	-65	-72	-77	-81	-81	-82	-83	-84	-84	-83	-78	-72	-64	-44	-34	-22	-13	-17	-14	-15	0	11	22	38	33	30	27	19	16	14	13	13	0	0	0
Other income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-16	-22	-20	-45	-41	-36	0	0	0	-	-	-
Other (expense) income, net
88	192	-25	-54	-55	-0	88	72	16	-81	-79	-2	-0	4	1	0	2	-6	-8	-11	24	30	37	46	8	6	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on exchanges of convertible senior subordinated notes (due 2013)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-
Income before provision for income taxes
1,732	1,394	750	816	705	600	680	126	-54	-15	-107	270	216	-67	-163	-217	-390	-557	-660	-734	-701	-734	-896	-848	-753	-965	-706	-592	-543	-12	279	484	324	60	-359	-759	0	-	0	0	-	-	-	-	-
Provision for income taxes
221	218	-1,368	-1,373	-1,422	-1,486	15	-117	-123	-107	-125	1	15	16	22	23	35	30	33	35	6	6	-150	-151	-154	-285	-132	-113	-91	38	64	14	19	19	0	0	0	-	-	-	-	-	-	-	-
Loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-741	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from discontinued operations, net of tax benefit of $0, $0 and $0, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-7	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
-	-	-	-	-	2,087	664	244	69	91	17	268	201	-84	-186	-240	-425	-588	-694	-770	-708	-742	-746	0	0	0	-	-478	-451	-51	215	470	305	41	-327	-764	-765	-754	-732	-673	-644	-642	0	0	0
Loss attributable to noncontrolling interest
-	-	-	-	-	-9	17	-170	-156	-171	-178	9	24	28	32	34	-26	-31	0	0	0	-	-228	-233	-237	-242	-15	19	55	55	87	63	7	11	0	0	0	-	-	0	-	-	-	-	-
Net Income (Loss) Attributable to Parent
1,510	1,176	2,144	2,215	2,155	2,096	647	415	225	263	195	259	177	-112	-218	-275	-399	-556	-659	-734	-704	-738	-517	-471	-369	-445	-565	-498	-506	-107	127	406	297	29	-338	-759	0	-	0	0	-	-	-	-	-
Loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-737	-682	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-3	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss from continuing operations:
Basic (usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.74	-0.72	-0.68	-1.00	-	-0.53	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted (usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.74	-0.72	-0.68	-1.00	-	-0.53	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss from discontinued operations:
Basic (usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	-	-0.01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted (usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	-	-0.01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Per Share [Abstract]
Earnings Per Share, Basic
2.32	2.26	0.22	1.04	1.05	6.08	0.51	0.82	0.83	0.40	-0.41	0.07	1.01	0.13	-0.16	-0.26	-0.17	-0.31	-0.39	-0.78	-0.83	-0.74	-0.72	-0.68	-1.00	0.19	-0.54	-0.26	-1.43	-0.35	-0.27	-0.31	0.44	0.76	1.06	-0.85	-0.87	-0.90	-1.04	-1.00	-0.83	-0.86	-0.84	-0.99	-1.04
Earnings Per Share, Diluted
2.29	2.23	0.22	1.03	1.03	5.97	0.50	0.80	0.81	0.39	-0.41	0.07	0.99	0.13	-0.16	-0.26	-0.17	-0.31	-0.39	-0.78	-0.83	-0.74	-0.72	-0.68	-1.00	0.19	-0.54	-0.26	-1.43	-0.35	-0.27	-0.31	0.43	0.74	1.02	-0.85	-0.87	-0.90	-1.04	-1.00	-0.83	-0.86	-0.84	-0.99	-1.04
Shares used in per share calculations:
Weighted Average Number of Shares Outstanding, Basic
259	258	256	256	255	254	254	254	253	251	250	247	246	245	244	244	243	243	241	240	239	238	236	233	232	231	230	222	215	214	213	211	208	206	206	204	202	201	200	200	198	185	178	172	155
Weighted Average Number of Shares Outstanding, Diluted
263	262	260	259	260	259	259	258	258	256	250	251	248	247	244	244	243	243	241	240	239	238	236	233	232	235	230	222	215	214	213	211	219	217	219	204	202	201	200	200	198	185	178	172	155
Product revenues, net
Revenues
4,818	4,160	3,615	3,448	3,257	3,038	2,791	2,558	2,322	2,165	1,998	1,858	1,769	1,683	1,636	1,529	1,263	1,000	718	553	515	487	491	541	673	837	990	1,106	1,225	1,333	1,508	1,625	1,326	950	0	0	0	-	-	0	-	-	-	-	-
Collaborative and royalty revenues
Revenues
0	2	4	6	7	9	37	64	92	323	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty revenues
Revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	16	19	20	20	23	26	29	36	40	69	87	123	156	163	161	146	141	123	106	82	50	33	32	29	30	30	29	28	28	0	0	0
Collaborative revenues
Revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	1	6	7	7	8	13	45	48	51	226	200	204	217	41	40	45	52	124	348	366	409	385	170	164	113	81	82	71	73	0	0	0